Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) EBIT (2020 - 2026)

Climb Bio filings provide 7 years of EBIT readings, the most recent being -$15.2 million for Q1 2026.

  • Quarterly EBIT rose 33.92% to -$15.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$60.1 million through Mar 2026, up 41.12% year-over-year, with the annual reading at -$67.9 million for FY2025, 17.24% up from the prior year.
  • EBIT hit -$15.2 million in Q1 2026 for Climb Bio, up from -$19.3 million in the prior quarter.
  • Across five years, EBIT topped out at -$3.0 million in Q1 2024 and bottomed at -$56.4 million in Q2 2024.
  • Average EBIT over 5 years is -$14.7 million, with a median of -$11.7 million recorded in 2024.
  • Peak annual rise in EBIT hit 87.18% in 2024, while the deepest fall reached 739.62% in 2024.
  • Climb Bio's EBIT stood at -$9.6 million in 2022, then soared by 46.39% to -$5.1 million in 2023, then plummeted by 113.02% to -$10.9 million in 2024, then tumbled by 76.85% to -$19.3 million in 2025, then grew by 21.17% to -$15.2 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's EBIT are -$15.2 million (Q1 2026), -$19.3 million (Q4 2025), and -$14.9 million (Q3 2025).